Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

[1]  Soo-Chang Song,et al.  Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential. , 2005, The international journal of biochemistry & cell biology.

[2]  Wei Wei,et al.  Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo , 2005, Cancer Chemotherapy and Pharmacology.

[3]  M. Berger,et al.  Convection-Enhanced Delivery of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand with Systemic Administration of Temozolomide Prolongs Survival in an Intracranial Glioblastoma Xenograft Model , 2004, Cancer Research.

[4]  D. Seol,et al.  The secretable form of trimeric TRAIL, a potent inducer of apoptosis. , 2004, Biochemical and biophysical research communications.

[5]  Xiao-Xia Xia,et al.  Purification and characterization of recombinant sTRAIL expressed in Escherichia coli. , 2004, Acta biochimica et biophysica Sinica.

[6]  Y. Youn,et al.  Monitoring of peptide acylation inside degrading PLGA microspheres by capillary electrophoresis and MALDI-TOF mass spectrometry. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[7]  A. Ashkenazi,et al.  Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. , 2003, Cytokine & growth factor reviews.

[8]  K. Totpal,et al.  Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. , 2001, The Journal of pharmacology and experimental therapeutics.

[9]  S. S. Strom,et al.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.

[10]  K. Famulski,et al.  Functional analysis of tumour necrosis factor-α-related apoptosis-inducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine , 2000 .

[11]  J. Tschopp,et al.  Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL* , 2000, The Journal of Biological Chemistry.

[12]  M. Ultsch,et al.  A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. , 2000, Biochemistry.

[13]  M. Ultsch,et al.  Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. , 1999, Molecular cell.

[14]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[15]  Lars E. French,et al.  The TRAIL to selective tumor death , 1999, Nature Medicine.

[16]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[17]  J. Tschopp,et al.  Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity , 1998, The Journal of experimental medicine.

[18]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[19]  R. Smith,et al.  The active form of tumor necrosis factor is a trimer. , 1987, The Journal of biological chemistry.

[20]  G. Gifford,et al.  Purification and physico-chemical characterization of rabbit tumor necrosis factor. , 1980, Journal of immunology.

[21]  M. Ahmad,et al.  Functional analysis of tumour necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. , 2000, The Biochemical journal.